Insider Trading Activity Bioverativ Inc (NASDAQ:BIVV) – Director Bought 2,000 shares of Stock

Insider Trading Activity For Bioverativ Inc (NASDAQ:BIVV)

Louis J Paglia , Director of Bioverativ Inc (NASDAQ:BIVV) reportedly Bought 2,000 shares of the company’s stock at an average price of 59.7 for a total transaction amount of $119,400.00 SEC Form

Insider Trading History For Bioverativ Inc (NASDAQ:BIVV)

On 5/24/2017 Brian S Posner, Director, bought 2,000 with an average share price of $53.86 per share and the total transaction amounting to $107,720.00.View SEC Filing

On 5/26/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $57.76 per share and the total transaction amounting to $115,520.00.View SEC Filing

On 5/30/2017 Alexander J Denner, Director, bought 90,000 with an average share price of $55.93 per share and the total transaction amounting to $5,033,700.00.View SEC Filing

On 6/28/2017 Diantha Duvall, Insider, sold 818 with an average share price of $60.47 per share and the total transaction amounting to $49,464.46.View SEC Filing

On 8/7/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $59.70 per share and the total transaction amounting to $119,400.00.View SEC Filing

Analyst Ratings For Bioverativ Inc (NASDAQ:BIVV)
These are 1 Sell Rating, 7 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Bioverativ Inc (NASDAQ:BIVV) is Hold (Score: 2.43) with a consensus target price of $58.17 , a potential (2.06% downside)

Analyst Ratings History For Bioverativ Inc (NASDAQ:BIVV)

• On 2/7/2017 Raymond James Financial, Inc. Initiated Coverage of rating Strong-Buy with a price target of $59.00
• On 2/8/2017 Morgan Stanley Reiterated Rating Underweight with a price target of $41.00
• On 2/28/2017 Piper Jaffray Companies Upgraded rating Neutral to Overweight with a price target of $44.00 to $65.00
• On 3/13/2017 Goldman Sachs Group, Inc. (The) Downgraded rating Buy to Neutral with a price target of $55.00
• On 3/27/2017 Stifel Nicolaus Boost Price Target of rating Buy to Buy with a price target of $54.00 to $57.00
• On 3/28/2017 Leerink Swann Set Price Target of rating Buy with a price target of $62.00
• On 3/31/2017 Argus Initiated Coverage of rating Hold to Hold with a price target of $51.00

Recent Trading Activity for Bioverativ Inc (NASDAQ:BIVV)
Shares of Bioverativ Inc closed the previous trading session at 59.39 down -1.29 -2.13% with 1,049,600 shares trading hands.